An estimated 71 million people worldwide live with chronic hepatitis C virus (HCV) infection which, if left untreated, can increase morbidity and mortality. Direct-acting antivirals (DAAs) are curative treatments for HCV. However, initiation of these treatments depends on access to health care and physicians that can diagnose and initiate treatment.
The aim of this study is to understand the relationship between DAA treatment rates and distance to prescriber in Ontario, Canada.
The following maps examine trends in HCV DAA medication prescribing and the average distance to a prescriber by public health unit in Ontario in 2019.
Access the full article and associated resources:
Additional related research conducted by the ODPRN:
Prescribing trends of direct acting antivirals for the treatment of hepatitis C in Ontario, Canada
Spending on hepatitis C antivirals in the United States and Canada, 2014 to 2018
